Shattuck Labs upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright upgraded Shattuck Labs (STTK) to Buy from Neutral with a $6 price target The firm cites its bullish stance on the company’s SL-325 program for the upgrade. Shattuck “has the potential for major differentiation” with SL-325, the analyst tells investors in a research note. H.C. Wainwright says the company’s “differentiation and ability to target and effectively antagonize DR3 activity, while others have not, stems largely from its antibody engineering expertise.”